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ABSTRACT 
 
The purpose of this study was to explore patient and family views on the sharing of 
their medical data in the context of compiling a European leukodystrophies database. A 
survey questionnaire was delivered with help from referral centers and the European 
Leukodystrophies Association, and thequestionnaires returned were both quantitatively 
and qualitativelyanalyzed. This study found that patients/families were strongly in favor 
of participating. Patients/families hold great hope and trust in the development of this 
type of research. They have a strong need for information and transparency on database 
governance, the conditions framing access to data, all research conducted, partnerships 
with the pharmaceutical industry, and they also needaccess to results. Our findings 
bring ethics-driven arguments for a process combining initial broad consent with 
ongoing information. On both, we propose key item–deliverables to database 
participants. 
 
 
Key words: Rare disease; Leukodystrophies; Database; Questionnaires; Informed 
Consent; Patient opinion. 
 
 
 3 
INTRODUCTION 
There is growing recognition of the value of collecting and sharing data on a globalized 
scale, particularly in the context of rare diseases where research on health records from 
the largest number of patients is crucial. The European Commission has recommended 
gathering national expertise predicated on the strategic importance of patients‘ registries 
in the field of rare diseases
1,2
. One of the objectives of the EU LeukoTreat program 
(2010-14) was to gather clinical and biological data on patients with leukodystrophies 
(LDs). LDs are a group of rare genetically-inherited neurodegenerative diseases of the 
white matter and its main component, myelin. More than twenty different types of LDs 
have been identified which can be inherited in a recessive, dominant, or X-linked 
manner, depending on the type, gene involved, and mutation. LDs predominantly affect 
young children but can also hit adults, causing cognitive deficits and potential loss of 
autonomy. Prevalence is approximately 1 in 10,000 of the population, with around 1,000 
new cases reported every year in Europe. Despite great strides in terms of advances in 
each individual LD, there is currently still no curative therapy
3,4
. 
The aim of the LeukoDataBase is to foster epidemiological research, help develop 
therapeutic approaches, and facilitate recruitment in clinical trials. The referring clinical 
centers gather socio-demographic and medical data extracted from patient records, 
including biological, genetic analyses and cognitive evaluations. The use of personal 
health information in research changes the perception of ethical regulations to protect 
human subjects. Here, the integrity of the body is less a concern than in clinical trials, 
but the concept of protection of human subjects has to factor in issues such as privacy, 
conditions of access to the data, consent and information
5
. In 1995, the EU Data 
Protection Directive restricted access to data unless consent had been obtained from the 
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subject, with exceptions made in cases of health-related research in the public interest
6
. 
At international level, ethical frameworks need to be established across national borders 
to allow large-scale data sharing, particularly in rare diseases where data needs to be 
collected from patients in different countries. In 2012, the EU proposed a legal 
framework on the protection of personal data
7
 to strengthen individual rights in a wider 
context of rapid technological progress and globalization. Experts are also working to 
establish general principles and tools to reach a consensus on promoting ethical 
regulation at international level
8,9
. The principles of information and initial consent have 
gained consensus, but there is ongoing debate over the information content
11
. The 
challenge is to determine what kind of consent would cover future research and what 
changes in research orientations would require fresh consent. 
The aim of this study was to optimize the information and consent process to meet 
participants‘ expectations against the background of the LeukoTreat project database. A 
survey questionnaire was used to explore patient/family motivations and reluctances to 
share health data at European level. This approach was carried out in synergy with 
ethical management of the project
12
 to better integrate the wishes of patients, 
particularly in terms of information and conditions of participation. 
METHODS 
Survey design  
Given the characteristics of LDs, the questionnaire was issued to patients and their close 
relatives. It was built by a panel of experts from medical pediatric genetics, psychology, 
medical ethics, and patient associations. The questionnaire was composed of close-
ended questions, most of which included the options for adding comments. The 
questionnaire was first tested during the European Leukodystrophies Association (ELA) 
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Families/Scientists meeting in Paris in 2011.Analysis of the 55 questionnaires returned 
guided the construction of the final revised version, which was translated (by A-T-T, 
Clermont-Ferrand, France) into English, Spanish, Italian and German.  
An information document inviting persons to participate in the study described 1) the 
goal of the research, 2) the LeukoTreat partners in charge of the survey, 3) the way 
participants can gain access to results, and 4) the fact that the survey is completely 
anonymous. None of the questions led to potentially identifying elements in responses. 
Questionnaire, information document and survey delivery process were all validated by 
the Ethics Committee in charge of the project. 
Survey distribution and delivery 
Information document and questionnaire were distributed in the different countries via 
two vectors:  
- Via the ELA network: in France, directly to patient and relatives during the ELA 
Families/Scientists annual meeting in 2012; outside France, via referral partners met or 
contacted by mail to explain the objectives of the survey and facilitate survey 
distribution and delivery.  
- Via referral clinical centers in France and in countries of LeukoTreat partners. A 
contact person was identified in each center.  
The number of questionnaires to be distributed was evaluated with input from ELA and 
clinical-center contact persons, and that number was then sent out to them (with pre-
paid return envelopes) for distribution. A total 250 questionnaires were delivered in 
France, 100 in Germany and Italy, and 50 in Belgium and Spain.   
Survey analysis 
Survey data were entered into an Excel spreadsheet. Results were expressed in 
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percentages. All participant comments were listed; here we cite the most 
representativeonesfor better specify the answers given and the arguments for and 
against. 
RESULTS 
In total, 195 questionnaires were returned: 149 from relatives (96 mothers, 43 fathers, 
10 close relatives)and 46 from patients. Despite significant difference in number of 
answers from these two groups, the choice was made to analyze them separately. In 
contrast, the significant difference in numbers of answers from each country [130 from 
France (23 patients) vs 24 from Italy (2 patients), 9 from Belgium (2 patients), 6 from 
Spain (1 patient), 26 from Germany (18 patients)] ruled out per-country analysis. 
Profile of respondents 
The majority of respondents are in the 40 to 64 years age bracket (90/149relatives,and 
31/46patients) and have been aware of the diagnosed disease for over 5 years 
(83/149relatives and 41/46patients). Genetic diagnosis has been established in most 
cases (102/149 relatives and 45/46 patients).A majority of respondents belong to one or 
more patient organizations (130/195-relatives 98/149: patients 32/46). In total, 66% of 
respondents all countries combined and 73% of respondents in France are members of a 
patient organization. 
Participation in the database 
As shown in Table 1,a majorityof respondents would agree to participate in research 
that collects data for leukodystrophies. Nearly all spontaneous comments highlight that 
the main reason for participating is to promote the advancement of research andthey 
specify that the objective is to find a treatment, cure the disease, halt its progression or 
advance its diagnosis. The importance of providing data for researchers is widely 
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recognized:―leukodystrophies are little-known diseases. Patients are key to advancing 
research by providing data to researchers‖, ―the more information collected, the more 
it will promote advancement of research‖, ―in a rare disease like this, maximum 
participation is required for effective research‖. The possibility to access clinical trials 
is occasionally mentioned.   
Limits to participation include concerns over patient wellbeing and a desire to avoid 
practical disability-related difficulties: ―may tire the patient‖, ―could lead to 
unnecessary further testing, sample-taking and painful examinations‖,―risk of 
distressing displacement linked to travel (more difficult if the disease progresses)‖, ―to 
advance medical research provided it does put added constraints on our son‖, ―loss of 
precious time devoted to my child‖. Two parents expressed the fear that use of the data 
may be diverted from the primary objective.  
As shown in Table 2, 7 out of the 8 motivations proposedappear particularly important: 
for relatives it is ―to face up to the disease‖; for patients it is a―better understanding of 
how the disease progresses‖.  
Conditions of access for research purposes 
Data security and confidentiality is an essential prerequisite to participation for 75.4% 
of respondents (107relatives and 40 patients) (data not shown). 
Access for researchers outside the project  
A large majority of patients and relatives are in favor of opening access to the database 
to researchers not involved in the LeukoTreat project, whether for research on LDsor on 
other diseases (Table 3). Respondents highlight the following points: ―no objection if 
researchers pledge to respect a good practice charter‖, ―sharing data with a lot of 
researchers in different countries is a plus to improve research‖, ―the effort to combat 
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the disease must be global, it will be stronger‖, ―the disease has no frontier‖, ―it is 
necessary to multiply, federate and pool research‖. Some express reservations: ―ensure 
confidentiality of international exchanges‖, ―everything depends on the political 
orientations of the nations‖, ―the rights of individuals should be respected‖, and ―be 
attentive to financial issues‖. 
Access for the pharmaceutical industry 
A majority of respondents are in favor, a minority are against and a large minority have 
no opinion on this issue (Table 4).Those in unconditional favor point out that 
―collaboration is necessary for the development of treatments‖ and ―the only important 
thing is progress and hope for a better future‖, but most respondents express 
reservations: ―on condition that, iftreatment innovations are achieved through use of 
patient data, then the treatments will be accessible at affordable prices to all patients‖, 
―if anonymity is preserved‖, ―if transparency is ensured‖, ―if I am informed about the 
objectives and the results‖, ―if the partnership is not driven by profit incentives only‖ 
and ―the database should not become owned by the pharmaceutical industry‖. One 
respondent expressed strong opposition: ―If there is such a partnership, I refuse to 
participate in the database. The pharma industry orients research in their own interests, 
not in the interests of patients‖.  
Conditions governing access by health professionals, patients and relatives   
A vast majority of relatives (95.9%) and patients (91.3%) are unconditionally in favor 
of opening access to their specialist physician (data not shown)—the very few 
exceptions revealed bad patient–physician relationships. Opening access to the family 
doctor received a less favorable response rate (relatives 75.8%, patients 71.7%) (data 
not shown). Reasons cited by those in favor included ―for them to better understandthe 
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disease‖, ―important for follow-up‖, ―he/she assists the patient in everyday life, so it is 
essential‖ and ―he/she can help us understand the scientific terms‖. Those expressing 
reservations state the lack of expertise on rare diseases or that ―when it comes to specific 
points, my doctor does not feel particularly concerned‖.  
A majority (87%) of patients wish to have unconditional access to their own data (data 
not shown). Reasons cited include ―I am the one most involved‖, ―I have the right to 
know and to be informed about the evolution of the disease in order to organize my 
future‖, ―nothing must be hidden to the patient‖. Those who express reservations 
(10.9%) set out the need for a psychological and educational approach (struggle to 
understand the data or to face up to it alone): ―depends on the nature of the data‖, ―who 
delivers it‖, or ―dataare too complex, a health professional needs to give explanations‖.  
Concerning opening access to their relatives, 26.1% of patients are fully opposed and 
36.9% express reservations (data not shown). They stress that ―this is a disclosure of 
medical confidentiality‖, ―access on condition that the patient consents‖, ―depends on 
the family’s relationship and degree of parenting‖.  
Length of data conservation  
Most respondents think it justifiable to continue the storage and use of data after the 
patient‘s death (Table 5). However, a significant number of patients have no opinion on 
this point.Comments include ―very important for next generations‖, ―data is precious as 
it is complicated to collect‖, ―important not to destroy it‖. For several relatives, the use 
of data for science helps make sense of the patient‘s death. They state that ―the research 
timeframe is often longer than the life of a patient‖, ―research must not stop‖, 
―destruction of the data would be a loss for research and we would be failing the 
deceased‖, ―my child has died, I’ll be happy to know that his data is a useful legacy for 
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scientific advancement‖, ―destroy what was collected is very selfish‖, and ―I trust 
researchers—if they keep the data and samples, they have good reasons to do so‖. 
Some express conditions: “that confidentiality is respected‖, ―if my son has not objected 
previously‖, ―if this question has been previously discussed‖, ―if I gave prior consent‖, 
―illegitimate if the family has not been informed‖, ―if it concerns the disease‖. One 
relative was opposed: ―I will struggle to deal with the fact that there are still things of 
my child that I do not control‖.   
Patient involvement in data processing  
Most participants would agree to enrich the database by self-entering data on daily life 
and follow-up parameters (Table 6), but a large proportion would prefer to do it with 
the help of a professional. More than 88% of relatives and 85% of patients would agree 
to enter the following types of data (data not shown): evolution of the disease, 
physical/psychological/behavioral changes, learning disabilities, feeding difficulties, 
treatment compliance and side effects, changes in pain and quality of life. 
The qualitative analysis reveals the motivations of participants: ―to support research by 
providing evidence‖, ―to optimize knowledge of the day-to-day impact of the disease‖, 
―to enable studies of quality of life and to enrich the database‖, ―toimprove the quality 
of medical care‖, ―because I know my child better than anyone‖, ―inform about things 
that researchers would not have thought‖, ―help collect daily data that is useful for 
some research‖. In addition, many underline the importance of participating in a 
collective approach ―to feel more of an actor in a human chain of solidarity‖. 
A few reservations emerged: ―if I am confident in the system collecting the data‖, ―if my 
child agrees‖ and ―depends what kind of data‖.  
Database as a bridge to clinical trials  
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A strong motivation to participate in the database is access to clinical trials (82.6% of 
relatives and 78.3% of patients) (see Table 2). In response to the question ―There are 
eligibility and ineligibility criteria governing participation in clinical trials; were you 
aware of this?‖, 53% of relatives and 43.5% of patients said yes (data not shown). 
Answers to an open-ended question investigating the information they would like to 
receive about a clinical trial clearly show the desire to receive as much information as 
possible: ―to know everything in detail‖, ―information throughout the trial‖, ―to be 
informed about all thebenefits andrisks‖ and the ―side effects and long-term effects‖, ―to 
know the impact for health‖. They also wantbe informed about the organizational 
conditions: ―constraints‖, ―conduct of the trial‖, ―duration‖.  
Asked whether patient organizations should play a role in the drafting and design of 
clinical trials(Table 7), 48.3% of relatives and 26.1% of patients answered yes.  
The comments partly explain the observed differences between relatives and patients‘ 
numbers of positive responses. Relativessee patient organizations in a support role: ―to 
ensure patient safety‖, ―to ensure maximum transparency‖, ―to help make information 
more understandable‖, ―to provide elements that researchers do not necessarily think 
of‖, ―to better account for the social and financial consequences of the trial‖, ―to help 
with practical organization of the trial‖, ―to help embed the prerequisite condition of 
patient access to research results‖.Patients show more trust in research professionals 
due to their competence and responsibility: ―it is important to clearly identify and 
segregate roles and responsibilities‖, ―this is the work of medical scientists‖, 
―information is confidential and only concerns the medical profession and the patient, 
not the associations. Everyone in their place‖. 
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The research program included an Ethics Committee. What do you expect from it? 
This open-ended question elicited a response from122respondents, and all emphasized 
its importance. For them, the role of such an ethics committee is to protect―patients’ 
rights over time and privacy‖, ensure ―respect of confidentiality and 
secrecy‖,―ensurecompliance with commitments and object to some decisions if 
necessary‖, ―respect for the Charter framing the database‖, ―respect for the dignity and 
wishes of patients‖, ―transparency on the use of data‖. Furthermore, it should―avoid 
financial drift‖. At the same time, they insisted on the importance of―not blocking the 
advancement of research‖, and some expressed that the committee ―should listen to the 
problems and expectations of families‖. 
Need for information  
Table 8 shows that most respondents want information on research results and on the 
possible evolution of the disease. To a lesser degree, they also want information on new 
research directions and general feedback on how the database is evolving and the 
scientific publications produced. Comments specify that they expect information on 
―how the data are used‖, ―what type of research stems from the database we are 
contributing to‖, “causes of the disease for undetermined 
leukodystrophies‖,―progression of the disease and impact for the future (potential 
deficits)‖, ―links between leukodystrophies and other diseases‖, ―existence of clinical 
trials and the type of leukodystrophy concerned‖, ―advancement of therapeutic 
solutions‖. 
Many wish to be informed once or twice a year (59% of relatives, 63% of patients), 
preferably by their specialist physician (67.8% of relatives, 83.3% of patients) or the 
referral center team (69.8% of relatives, 50% of patients) (data not shown). Participants 
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are also interested in receiving information via newsletters (by email or paper) or via a 
dedicated website.  
DISCUSSION  
This study explores the views of patients and their families affected by leukodystrophies 
in the setting of a European database. 
Strong adhesion 
A major result is that patients/families are strongly driven to participate in any research 
that collects data. This is explained by the fact that patient registries and databases are 
widely recognized as highly vital in the context of rare diseases, and health data 
collection is often an integrated functional process in centers of expertise where clinical 
care and research are intimately linked
2,13
. For patient organizations, the development of 
international databases and registries is a political priority
14
.  
All the qualitative comments in our study point to advancing research as the main 
motivation for participation. Indeed, patients are aware that data sharing by the largest 
number at global level is the way to better understand their diseases and accelerate the 
research and development process. They are on the frontline in terms of facing up to the 
disease and the deficit of curative treatments. Motivation is also reflected by the fact 
that nearly all respondents would be willing to participate by self-populating the 
database with data on their daily life and evolution of their disease. They consider this 
type of data as highly relevant and complementary to data collected by doctors and 
researchers. 
Their comments show the wish to be engaged in a collective struggle against the disease 
with an altruistic dimension of helping other patients, as already observed in other 
studies: participants know they are contributing to an enterprise that aims to improve the 
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wider human condition rather than benefit individually
15-17
. For the respondents in our 
study, participating in a database helps belong to a community, which appears 
fundamental as a way to better face up to and make sense of the disease. Being a subject 
of interest for researchers is also essential given the difficulties involved in access to 
care and the feeling of exclusion associated with a rare disease. All these points are felt 
even more sharply in the context of rare diseases
18-20
. 
Data access: between trust and control 
Respondents have a high level of trust in the constitution and use of the database by 
researchers. This can be explained by the trust they have in professionals who jointly 
provide care and research missions, especially in the context of LDs where there is no 
real frontier between care and research
12
.  
However, respondents are vigilant over the conditions framing the constitution and use 
of the database. This is consistent with other studies showing that for the general 
population, the existence of ethical principles and rules accompanying data sharing is 
recognized as indispensable
20-23
. Communication and transparency on the conditions 
governing data usage are key to effective collaboration and trust 
17,24
. 
Survey respondents want to be assured of compliance with initial commitments through 
the consent and information they receive. Every professional involved in the project is 
expected to adhere to the ethical principles accepted by all partners. Moreover, the 
respondents are sensitive to monitoring by an ethics committee, the existence of which 
appears essential. In LeukoTreat, all these points are developed in a dedicated ethical 
charter
12
 signed by all partners. Any new research team wishing to access the database 
has to propose a scientific project to be evaluated by the program follow-up committee 
and commit to uphold the rules described in the charter. This principle was set in 
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agreement with the ELA patient association. The alternative, if any, would be to request 
a specific patient consent—an approach that in practice would prove impossible at 
operational level. This information should be given to the patient at initial consent. 
Regarding potential partnership with the pharmaceutical industry for access to the 
database, respondents tend to be more reserved or without opinion. Although 
respondents recognize the need for partnership with the pharmaceutical industry as 
valuable for therapeutic advance, they demand guarantees and transparency and want to 
be informed of the scientific and medical purposes as well as the results of the research. 
They express major concerns over the issue of profit that would not benefit the patients. 
Indeed, it has been shown that the fact that biobanks or registries are run publicly is an 
important factor for trust, and that commercialization, private interests and ownership 
issues can affect people‘s perceptions and willingness to participate6,25. Therefore, it 
appears important to communicate on any partnership with pharmaceutical industry 
partners. In any such partnership, participants‘ rights and expectations must be properly 
integrated as conditions governing contract collaborations
23
. Patients and patient 
organizations should thus be given some kind of control over the partnership-framework 
conditions governing patient data management and access in rare diseases
26
.  
Transparency on data storage and the length of data accessibility is also an issue. Most 
respondents agree on no time limitation, as they feel that the data are precious, 
especially in their context of rare disease. Storage even after a patient‘s death is viewed 
as legitimate as it contributes to the collective interest. This is in line with a 
recommendation from a European Commission expert group emphasizing that ―in the 
case of the overriding interest, even in the absence of consent given before death, their 
use could be legitimate: absence of consent should not be considered as equivalent to 
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non-consent‖27. For greater transparency, we believe participants should be informed on 
this point at the time of initial consent in order to clarify the situation while empowering 
participants who are opposed to opt out. This procedure would allow participants to 
give consent specifically on this point (as wished by some respondents in this study).  
Toward a broad and ongoing consent process?  
In registries and databases, consent is always a challenging issue. As they are designed 
for the long term, governance elements and associated research projects may evolve 
over time. Various approaches to database consent have been discussed, and the 
question raised is how to conciliate respect for autonomy, particularly the right to 
withdraw at any time, with the impracticalities of repeatedly asking for fresh consent on 
each new research orientation. This approach is always complex, sometimes impossible, 
and potentially detrimental to rare disease patient and research communities
28,29
.  
The traditional strictly specific consent used for medical research is designed for a 
specific study, for a clear period of time, and for defined investigators. This type of 
consent appears ill-suited to registries and has been hotly debated in biobank research.  
The principle of blanket consent (i.e. consent with no restrictions on future research) has 
been discussed in clinical practice
30
 and in biobanking
31
, but some consider it hard to 
accept in terms of patient information, validity of consent over time, and the possibility 
to exercise the right to withdraw
21,,32
.  
An alternative is broad consent
33,
, which means consenting to a framework of future 
research of a certain type. Broad consent makes it possible to promote the development 
of research in a large and pre-defined field, avoiding the need to re-consent. This model 
of ‗broad consent‘ has been adopted by many current biobank projects, includingthe UK 
Biobank, CARTaGENE (Montreal, QC, Canada) and the Norwegian HUNT study, 
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giving an early perception of consensus patterns. However, Master et al
34
 reviewed the 
literature on populations‘ preferences for different types of consent to biobanking, and 
found very diverse patterns of consent between countries, prompting a call for vigilance 
since consent practices are part and parcel of participant trust.  
Broad consent needs to be devised to always consider borderline situations, which 
should require re-consent if necessary
35,36.
 The question then becomes who is in charge 
of deciding whether or not participants need to be re-contacted for fresh consent? 
Hanson
24 
and Steinbeck
35
 tackled this issue by proposing to set up an independent ethics 
steering committee. Based on the patient expectations collected here, we advocate this 
procedure as it provides an independent decisional framework that can account for the 
views and standpoints of researchers, promoters and patients‘ representatives alike. 
Finally, we find that post-inclusion information is a major concern for patients and 
families, proving just as important as initial consent. Indeed, there is a growing body of 
evidence to show that participants want to be kept informed over time
37
.  
In the ethical management of LeukoTreat, we propose to optimize broad consent with 
ongoing information and oversight by an ethics steering committee (Table 9). This 
process appears optimal for promoting research that respects participant choices and the 
ethical validity of consent over the longer term. 
Limits of the study 
The lack of enough respondents to establish sub-groups limited the study of potential 
differences between patients/families from different countries or the effects of factors 
that could influence point of view such as form, evolution and seriousness of the disease 
or socio-economic factors. 
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Table 1Would you agree to participate in any research that collect data for 
leukodystrophies? 
 Relativesn=149 (%) Patientsn=46 (%) 
Yes 83.9 89.1 
No 1.3  
Don’t know 14.8 10.9 
 
 
 
 
 
Table 2 Scores of the reasons for participating according to how important you rate the 
following items? 
Important-Very important 
Relatives  
n=149 (%) 
Patients  
n=46 (%) 
A better understanding of how the disease progresses 
(prognostic markers) 
89.3 97.8 
A better understanding of the disease causes 89.9 89.1 
Access to clinical trials 82.6 78.3 
Discoveries with therapeutic impact for you/your relative 91.3 91.3 
Discoveries with no therapeutic impact for you/your relative 82.6 78.3 
More efficient diagnostic tests (diagnostic markers) 91.3 82.6 
To belong to a community 70.5 54.3 
To face up to the disease  90.6 89.1 
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Table 3Under certain conditions, researchers outside LeukoTreat may be able to 
access the database at their request. How do you feel about giving database access 
to outside researchers? 
For research on : Leukodystrophies Others diseases 
 
Relatives  
n=149 (%) 
Patients 
n=46 (%) 
Relatives 
n=149 (%) 
Patients 
n=46 (%) 
Without reservations 89.9 76.1 76.1 64.1 
With reservations 5.4 10.9 10.9 10.9 
Opposed 0.7 10.9 2.2 7.6 
 
 
 
Table 4 Pharmaceutical industry partnership may develop diagnostic or therapeutic 
innovation and/or contribute to research funding.  Would you agree to the use (or your 
relative’s) data in such partnership? 
 Relatives    n=149 (%) Patients      n=46 (%) 
Yes 61.1 65.2 
No 6.7 13 
Don’t know 27.5 21.7 
 
 
 
Table 5 The storage of data after patient ‘death is controversial. In your opinion, the 
continued storage and use of the data and biological samples in this case is: 
 Relativesn=149 (%) Patients       n=46 (%) 
Justifiable 82.6 69.6 
Wrong 2 2.2 
Don’t know 11.4 28.3 
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Table 7 In your opinion, should patients’ organizations play a role in the drafting 
and design of a clinical trial protocol?  
 Relatives n=149 (%) Patients n=46 (%) 
Yes 48.3 26.1 
No 17.4 30.4 
Don’t know 28.2 37 
 
 
Table 8 What information would you like to receive from the 
Leukodatabase?(Several possible answers) 
Expectation in terms of information 
Relatives 
n=149 (%) 
Patients 
n=46 (%) 
On  the possible evolution of the disease 87.2 93.5 
On new research directions 73.8 67.4 
On research results 89.9 93.5 
On scientific publications related to research  66.4 58.7 
On general information from the database 
(number of patients included, changes, etc.) 
57.1 63 
Table 6 Would you agree to enter your own data (or your relative’s)? 
 Relatives n=149 (%) Patients n=46 (%) 
Yes 94 91.3 
No 2 2.2 
Don’t know 0.7 0 
If yes Relatives (%) Patients (%) 
On my own 55.7 43.5 
With the health 
professional 
35.6 47.8 
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Table 9 Key information factors for database participants 
Initial information for broad consent Ongoing information 
 
1) Nature of data collected and purposes of the 
database 
 
2) Data security and confidentiality 
 
3) Length of storage with/without limit 
 
4) Database ownership and governance 
 
5) Conditions governing academic and 
pharma-industry partnerships 
 
6) Commitment to give ongoing information 
 
7) Existence of an ethics steering committee  
 
1) Growth of the database 
 
2) New research orientations  
 
3) Setting up clinical trials  
 
4) Research results 
 
5) New partnerships (academic 
and/or pharma-industry) 
 
6) Change in database ownership 
and governance  
 
